New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
10:53 EDTSNSS, BWP, FWM, IMAX, CYOUHigh option volume stocks: BWP CYOU FWM SNSS IMAX
News For BWP;CYOU;FWM;SNSS;IMAX From The Last 14 Days
Check below for free stories on BWP;CYOU;FWM;SNSS;IMAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
06:20 EDTIMAXIMAX and China's WASU Group sign home theater content delivery agreement
IMAX and TCL Multimedia Technology Holdings announced a joint-venture partnership with Wasu Digital TV Media Group as part of their IMAX TCL home theatre initiative. WASU will license and distribute IMAX-enhanced Hollywood and Chinese current theatrical and other content to the IMAX-TCL premium home theatre system.
06:20 EDTIMAXIMAX and China's WASU Group sign home theater content delivery agreement
Subscribe for More Information
06:20 EDTIMAXIMAX, China's WASU Group announces content delivery agreement for IMAX-TCL
Subscribe for More Information
April 14, 2014
10:02 EDTBWPOn The Fly: Analyst Upgrade Summary
Acorda Therapeutics (ACOR) upgraded to Outperform from Market Perform at FBR Capital... Allegheny Technologies (ATI) upgraded to Neutral from Underperform at Sterne Agee... BP (BP) upgraded to Buy from Hold at Canaccord... Bloomin' Brands (BLMN) upgraded to Buy from Hold at Deutsche Bank... Boardwalk Pipeline (BWP) upgraded to Neutral from Underperform at BofA/Merrill... Boston Scientific (BSX) upgraded at BofA/Merrill... Charles Schwab (SCHW) upgraded to Buy from Neutral at UBS... Citigroup (C) upgraded to Hold from Sell at Rafferty Capital... Community Health (CYH) upgraded to Outperform from Perform at Oppenheimer... Eaton Vance (EV) upgraded to Neutral from Sell at Citigroup... Eli Lilly (LLY) upgraded to Hold from Underperform at Jefferies... F5 Networks (FFIV) upgraded to Buy from Hold at Stifel... HeartWare (HTWR) upgraded to Buy from Neutral at BTIG... Heartland Payment (HPY) upgraded to Hold from Sell at Stifel... Hyatt Hotels (H) upgraded to Outperform from Market Perform at FBR Capital... MasterCard (MA) upgraded to Outperform from Neutral at RW Baird... McDermott (MDR) upgraded to Neutral from Underweight at HSBC... Palo Alto (PANW) upgraded to Overweight at Stephens... PetroChina (PTR) upgraded to Neutral from Underperform at Credit Suisse... Seagate (STX) upgraded to Buy from Hold at Argus... Sensata (ST) upgraded to Buy from Neutral at Citigroup... Stryker (SYK) upgraded to Neutral from Reduce at SunTrust... TD Ameritrade (AMTD) upgraded to Buy from Neutral at UBS... TTM Technologies (TTMI) upgraded to Buy from Hold at Stifel... Transocean (RIG) upgraded to Hold from Sell at Deutsche Bank... VMware (VMW) upgraded to Outperform from Underperform at CLSA... Visa (V) upgraded to Outperform from Neutral at RW Baird... Yahoo (YHOO) upgraded to Buy from Neutral at SunTrust... Zimmer (ZMH) upgraded to Neutral from Reduce at SunTrust... bebe stores (BEBE) upgraded to Buy from Neutral at Janney Capital.
06:38 EDTBWPBoardwalk Pipeline upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill upgraded Boardwalk Pipeline to Neutral from Underperform based on reports it contracted some legacy pipeline capacity reversals and is working on others. Price target raised to $16 from $14.
April 10, 2014
06:25 EDTFWMCompetition, overexpansion hurting Whole Foods competitors, WSJ reports
Sales growth at specialty-grocery chains like Fairway (FWM), Sprouts (SFM) and Fresh Market (TFM), which feature natural and organic foods, has been hurt by competition and mistakes like overexpansion, the Wall Street Journal reports. These companies compete with Whole Foods (WFM). Reference Link
April 9, 2014
07:46 EDTIMAXIMAX China unit poised for IPO, says MKM Partners
Subscribe for More Information
April 8, 2014
13:30 EDTSNSSSunesis vosaroxin shown to be effective, says Wedbush
Wedbush believes that initial data from a Phase Ib/II study indicates that Sunesis' vosaroxin and decitabine are more effective in treating acute myeloid leukemia and myelodysplastic syndrome than decitabine alone. The firm notes that vosaroxin combined with decitabine appeared to be safe. It reiterates a $10 price target and Outperform rating on Sunesis.
13:00 EDTSNSSSunesis price target raised to $15 from $12 at Roth Capital
Roth Capital raised Buy rated Sunesis' price target to $15 from $12 based on positive Phase I/II combination data with vosaroxin in older front line AML patients announced at AACR.
11:26 EDTBWPBalyasny Asset reports 5.7% passive stake in Boardwalk Pipeline
Subscribe for More Information
08:11 EDTSNSSSunesis announces presentation of positive results from Vosaroxin trial
Subscribe for More Information
06:04 EDTIMAXIMAX sells 20% stake in IMAX China to strategic Chinese investors for $80M
Subscribe for More Information
06:02 EDTIMAXIMAX sells 20% stake in IMAX China to strategic Chinese investors for $80M
April 7, 2014
07:27 EDTSNSSAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
April 3, 2014
07:31 EDTIMAXIMAX expands partnership with Cineworld for additional 11 theatres
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use